These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 39295933)

  • 1. Case report: Therapeutic drug monitoring and CYP2D6 phenoconversion in a protracted paroxetine intoxication.
    Damborská A; Hanáková L; Pindurová E; Horská K
    Front Pharmacol; 2024; 15():1444857. PubMed ID: 39295933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.
    den Uil MG; Hut HW; Wagelaar KR; Abdullah-Koolmees H; Cahn W; Wilting I; Deneer VHM
    Front Genet; 2023; 14():1249164. PubMed ID: 37693320
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of phenoconversion in the pharmacogenetics of psychiatric medication.
    Hahn M; Roll SC
    Pharmacogenomics; 2023 Jun; 24(9):485-487. PubMed ID: 37427432
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
    Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
    Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.
    Hole K; Haslemo T; Molden E
    Ther Drug Monit; 2023 Oct; 45(5):683-688. PubMed ID: 37012633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OpenCYP: An open source database exploring human variability in activities and frequencies of polymophisms for major cytochrome P-450 isoforms across world populations.
    Vichi S; Buratti FM; Di Consiglio E; Turco L; S Lautz L; Darney K; Dorne JCM; Testai E
    Toxicol Lett; 2021 Oct; 350():267-282. PubMed ID: 34352333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.
    Koopmans AB; Braakman MH; Vinkers DJ; Hoek HW; van Harten PN
    Transl Psychiatry; 2021 Feb; 11(1):141. PubMed ID: 33627619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail.
    Lenoir C; Daali Y; Rollason V; Curtin F; Gloor Y; Bosilkovska M; Walder B; Gabay C; Nissen MJ; Desmeules JA; Hannouche D; Samer CF
    Clin Pharmacol Ther; 2021 Jun; 109(6):1668-1676. PubMed ID: 33341941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition and induction of CYP enzymes in humans: an update.
    Hakkola J; Hukkanen J; Turpeinen M; Pelkonen O
    Arch Toxicol; 2020 Nov; 94(11):3671-3722. PubMed ID: 33111191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review.
    Klomp SD; Manson ML; Guchelaar HJ; Swen JJ
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics.
    Schulz M; Schmoldt A; Andresen-Streichert H; Iwersen-Bergmann S
    Crit Care; 2020 May; 24(1):195. PubMed ID: 32375836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions.
    Scotton WJ; Hill LJ; Williams AC; Barnes NM
    Int J Tryptophan Res; 2019; 12():1178646919873925. PubMed ID: 31523132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.
    Gaedigk A; Ingelman-Sundberg M; Miller NA; Leeder JS; Whirl-Carrillo M; Klein TE;
    Clin Pharmacol Ther; 2018 Mar; 103(3):399-401. PubMed ID: 29134625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
    Hiemke C; Bergemann N; Clement HW; Conca A; Deckert J; Domschke K; Eckermann G; Egberts K; Gerlach M; Greiner C; Gründer G; Haen E; Havemann-Reinecke U; Hefner G; Helmer R; Janssen G; Jaquenoud E; Laux G; Messer T; Mössner R; Müller MJ; Paulzen M; Pfuhlmann B; Riederer P; Saria A; Schoppek B; Schoretsanitis G; Schwarz M; Gracia MS; Stegmann B; Steimer W; Stingl JC; Uhr M; Ulrich S; Unterecker S; Waschgler R; Zernig G; Zurek G; Baumann P
    Pharmacopsychiatry; 2018 Jan; 51(1-02):9-62. PubMed ID: 28910830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome.
    Gurrera RJ; Mortillaro G; Velamoor V; Caroff SN
    J Clin Psychopharmacol; 2017 Feb; 37(1):67-71. PubMed ID: 28027111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of CYP2D6 phenotype from genotype across world populations.
    Gaedigk A; Sangkuhl K; Whirl-Carrillo M; Klein T; Leeder JS
    Genet Med; 2017 Jan; 19(1):69-76. PubMed ID: 27388693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.
    Morgan ET
    Clin Pharmacol Ther; 2009 Apr; 85(4):434-8. PubMed ID: 19212314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition and induction of human cytochrome P450 enzymes: current status.
    Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
    Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.